Led · Series B · Dec 2024

PhotoniCare develops the OtoSight Middle Ear Scope, an FDA-cleared medical device that uses optical coherence tomography (OCT) high-resolution depth imaging to detect and characterize middle-ear fluid even in the presence of ear wax. The device is intended for frontline clinicians in pediatrics, family medicine, and urgent care to improve diagnosis, treatment, and monitoring of middle ear infections. OtoSight has unique CPT codes and has served more than 26,000 patients, indicating early commercial traction and a potential new revenue source for providers. The company has published three peer-reviewed manuscripts and has a large randomized controlled clinical trial (RCT) underway to support reimbursement strategy and broader adoption. PhotoniCare recently formed a manufacturing partnership with Gentex Corporation and relocated its headquarters from Champaign, Illinois to Grand Rapids, Michigan to work more closely with that partner. The company will use new funding to support the ongoing clinical trial, ramp production and sales of OtoSight, and complete its planned $9 million Series B close. PhotoniCare's core product, the TOMi Scope, is the first and only otoscope using Optical Coherence Tomography (OCT) to visualize and characterize fluid in the middle ear through the intact eardrum. The device measures fluid density even in the presence of wax, providing objective data to inform diagnosis of middle-ear infections. The TOMi Scope received FDA clearance in January. A 70-patient study with Children’s National demonstrated 91% sensitivity and 90% specificity for detecting middle-ear fluid. PhotoniCare plans to expand its executive team, ramp manufacturing, execute its sales and marketing plan, fuel AI development for real-time decision support, and expand reimbursement activities and customer support. Financially, the company announced new funding including a $5.2M Series A and a $2.1M Phase II SBIR grant to support commercial expansion and AI work.

Participated · Series A · Jul 2024

RetiSpec develops AI solutions applied to non-invasive retinal images to identify neurodegenerative disease markers and provide real-time results at the point of care. Its first clinically validated AI is intended to predict amyloid burden to aid evaluation for Alzheimer’s disease. RetiSpec’s solutions are currently available for Research Use Only. The company aims to enable widespread early and accurate detection of neurodegenerative disease through a routine eye exam. Leadership is headed by co-founder and CEO Eliav Shaked. The company is based in Toronto, Canada and has raised $17M USD to date.

Led · Series A · Jan 2018

Yonomi offers a platform that provides developers with the tools to build, integrate, and scale smart-home products and services. Its consumer app for iPhone and Android connects existing smart home devices and automates Routines and is used in more than 150 countries. Commercial offerings include Yonomi ThinCloud and Yonomi One, a SaaS solution that integrates products and services with major smart-home devices and platforms. The company has piloted Yonomi One with Gentex, which leveraged it to launch HomeLink Connect to trigger smart-home Routines from a vehicle. Yonomi plans to use new funding to expand worldwide, broaden device partnerships, and further market and scale its platform offerings. The company was founded in 2013 by Kent Dickson and operates out of Boulder, Colorado and Austin, Texas.